Table 2

Clinicopathological features of patients with AITL developing renal involvement
Author Sex Age Type of renal lesion Interval (months) Treatment Clinical outcome
Wood and Harkins [13] M 76 Diffuse proliferative glomerulonephritis 0 Corticosteroid, cyclophosphamide Dead for lymphoma
Wood and Harkins [13] M 79 Minimal change disease 0 Dialysis Dead for renal failure
Bhat et al [8] F 77 Acute renal failure with Bence-Jones proteinuria 4 None Dead for sepsis
Platzer et al [11] M 64 Renal failure 0 Prednisolone CR
Bello et al [15] M 61 Fanconi syndrome 0 Hydrocortisone CR
Bignon et al [23] M 70 Dysproteinaemia 0 n.a. n.a.
Yamazaki et al [26] M 72 Endocapillary proliferative glomerulonephritis 0 Vincristine, prednisolone Dead for alimentary tract bleeding
Nakamoto et al [10] M 40 Acute interstitial nephritis 16 Prednisolone, cyclophosphamide At 60-month follow-up, no signs of relapse
Duwaji et al [28] M 71 Proliferative glomerulonephritis 2 CHOP regimen Dead for sepsis
Lim et al [33] M 33 Amyloidosis 12 CHOP regimen At 12-month follow-up, no signs of relapse
Hamidou et al [12] M 56 Vasculitis 0 CHOP regimen Dead for renal failure
De Samblanx et al [2] M 67 Proliferative glomerulonephritis 0 CHOP regimen At 12-month follow-up, no signs of relapse
Goto et al [9] M 73 Direct invasion by lymphoma 0 CHOP regimen At 20-month follow-up, no signs of relapse
Miura et al [7] M 70 IgM-λ glomerular thrombi 2 CHOP regimen At 3-month follow-up, no signs of relapse
Tagashi et al [16] M 21 Nephrotic syndrome 0 CHOP regimen At 36-month follow-up, no signs of relapse

CR complete remission; n.a. not available, CHOP Cyclophosphamide, doxorubicin, vincristine, prednisolone.

Ambrosio et al.

Ambrosio et al. Diagnostic Pathology 2012 7:50   doi:10.1186/1746-1596-7-50

Open Data